- Home
- EM vs ADAP Comparison
EM vs ADAP Comparison
Compare EM & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EM
- ADAP
- Stock Information
- Founded
- EM 2017
- ADAP 2008
- Country
- EM China
- ADAP United Kingdom
- Employees
- EM N/A
- ADAP N/A
- Industry
- EM Other Consumer Services
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- EM Consumer Discretionary
- ADAP Health Care
- Exchange
- EM Nasdaq
- ADAP Nasdaq
- Market Cap
- EM 215.7M
- ADAP 212.3M
- IPO Year
- EM 2021
- ADAP 2015
- Fundamental
- Price
- EM $0.72
- ADAP $0.64
- Analyst Decision
- EM Strong Buy
- ADAP Strong Buy
- Analyst Count
- EM 1
- ADAP 4
- Target Price
- EM $1.00
- ADAP $3.16
- AVG Volume (30 Days)
- EM 52.4K
- ADAP 2.4M
- Earning Date
- EM 11-29-2024
- ADAP 11-13-2024
- Dividend Yield
- EM N/A
- ADAP N/A
- EPS Growth
- EM N/A
- ADAP N/A
- EPS
- EM 0.03
- ADAP N/A
- Revenue
- EM $269,745,696.00
- ADAP $175,041,000.00
- Revenue This Year
- EM N/A
- ADAP $180.15
- Revenue Next Year
- EM $6.16
- ADAP N/A
- P/E Ratio
- EM $22.05
- ADAP N/A
- Revenue Growth
- EM N/A
- ADAP 146.27
- 52 Week Low
- EM $0.43
- ADAP $0.42
- 52 Week High
- EM $1.18
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- EM 53.78
- ADAP 36.20
- Support Level
- EM $0.69
- ADAP $0.57
- Resistance Level
- EM $0.75
- ADAP $0.71
- Average True Range (ATR)
- EM 0.04
- ADAP 0.07
- MACD
- EM 0.00
- ADAP -0.01
- Stochastic Oscillator
- EM 78.57
- ADAP 22.70
About EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging service through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Through the mini-programs, users rent the power banks to carry with them when use the service and can return the power banks at any of the POIs, enabled by the expansive network and powerful technologies.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.